RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010
/PRNewswire-FirstCall/ — Chimerix, Inc., a pharmaceutical company
developing orally-available antiviral therapeutics, today
reaffirmed its commitment to the dual development of CMX001 as a
medical countermeasure against smallpox and as a broad-spectrum
antiviral agent. This statement follows notification from the
Small Business Administration (SBA) that it has determined that
SIGA Technologies, Inc. is not a small business, thus rendering
SIGA ineligible for award of a government contract from the
Biomedical Advanced Research and Development Authority (BARDA) that
was designated as a small business set-aside.
“Chimerix is deeply committed to developing and advancing safe,
effective medicines that benefit public health. We support
the efforts of the Department of Health and Human Services to
ensure that the government’s requirement for smallpox therapeutics
is met expeditiously and in accordance with Federal Acquisition
Regulations,” stated Kenneth I. Moch, President and Chief Executive
Officer of Chimerix.
“The most important advancement we have made in the clinical and
preclinical development of our lead antiviral candidate, CMX001, is
to establish its profile as a broad-spectrum therapeutic with the
potential to treat a number of fatal diseases. Our clinical
experience with patients to date keeps us extremely motivated to
see its development through registration and approval. Combined
with its potential to address the smallpox threat, we feel CMX001
is well positioned to address the broadest definition of unmet
medical need,” said Wendy Painter, M.D., M.P.H., Chief Medical
Officer of Chimerix.
CMX001 – An Antiviral with Broad-Spectrum
Activity
CMX001 is in advanced development as a medical countermeasure
for the treatment of smallpox. CMX001 has demonstrated
protection from mortality in animal models of human smallpox
disease in multiple pr
‘/>”/>
